Evidence map›Paper›PMID 32927889›Full record

ArticleCancers2020

Plasma Nucleosomes in Primary Breast Cancer.

Michal Mego, Katarina Kalavska, Marian Karaba, Gabriel Minarik, Juraj Benca, Tatiana Sedlackova, Paulina Gronesova, Dana Cholujova, Daniel Pindak, Jozef Mardiak and 1 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Epigenetic reprogramming in cancer: From diagnosis to treatment.Frontiers in cell and developmental biology · 2023
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Michal Mego2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, 83310 Bratislava, Slovakia.ORCID 0000-0002-6511-6827
Katarina KalavskaTranslational Research Unit, Faculty of Medicine, Comenius University and National Cancer Institute, 83310 Bratislava, Slovakia.
Marian KarabaDepartment of Oncosurgery, National Cancer Institute, 83310 Bratislava, Slovakia.
Gabriel MinarikInstitute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 81372 Bratislava, Slovakia.
Juraj BencaDepartment of Oncosurgery, National Cancer Institute, 83310 Bratislava, Slovakia.
Tatiana SedlackovaInstitute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 81372 Bratislava, Slovakia.
Paulina GronesovaBiomedical Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia.
Dana CholujovaBiomedical Center, Slovak Academy of Sciences, 84505 Bratislava, Slovakia.
Daniel PindakDepartment of Oncosurgery, National Cancer Institute, 83310 Bratislava, Slovakia.
Jozef Mardiak2nd Department of Oncology, Faculty of Medicine, Comenius University and National Cancer Institute, 83310 Bratislava, Slovakia.
Peter CelecInstitute of Molecular Biomedicine, Faculty of Medicine, Comenius University, 81372 Bratislava, Slovakia.ORCID 0000-0001-5883-3580
Comenius University Bratislava · SKBiomedical Research Center of the Slovak Academy of Sciences · SKSlovak Medical University · SKVysoká Škola Zdravotníctva a Sociálnej Práce sv. Alžbety · SK

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-16-0010Agentúra na Podporu Výskumu a Vývoja APVV-16-0178ERA-NET EuroNanoMed II INNOCENT ERA-NET EuroNanoMed II INNOCENTVedecká Grantová Agentúra MŠVVaŠ SR a SAV 1/0044/15Vedecká Grantová Agentúra MŠVVaŠ SR a SAV 1/0271/17Vedecká Grantová Agentúra MŠVVaŠ SR a SAV 2/0052/18Vedecká Grantová Agentúra MŠVVaŠ SR a SAV No. 1/0724/11
6 · The paper itself

Abstract

When cells die, nucleosomes composed of DNA and histone proteins enter the extracellular space and end eventually in the circulation. In plasma, they might serve as a nonspecific marker of cell death, potentially useful for noninvasive monitoring of tumor dynamics. The aim of this study was to analyze circulating nucleosomes in relation to patient/tumor characteristics and prognosis in primary breast cancer. This study included 92 patients with breast cancer treated with surgery for whom plasma isolated was available in the biobank. Plasma nucleosomes were detected in samples taken in the morning on the day of surgery using Cell Death Detection ELISA kit with anti-histone and anti-DNA antibodies. Circulating nucleosomes were positively associated with the systemic inflammatory index (SII), but not with other patient/tumor characteristics. Patients with high SII in comparison to low SII had higher circulating nucleosomes (by 59%,

Indexed as

circulating nucleosomescirculating tumor cellscytokinesplasminogen activator inhibitor-1primary breast cancer

Identifiers

PMID32927889
PMCPMC7563724
OpenAlexW3084024634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.